EmailPfizer (PFE $19.54 +0.29) reported third quarter earnings of $0.62 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus Estimate of $0.55.
Revenues rose 7.5% year/year to $17.19 billion versus the $16.43 billion consensus.
The company issued in-line guidance for fiscal year 2011 with EPS to $2.24-2.29, excluding non-recurring items, from $2.16-2.26 versus the $2.25 Capital IQ consensus and the company raised fiscal year 2011 revenues to $66.2-67.2 billion from $65.2-67.2 billion versus the $66.55 billion Capital IQ Consensus Estimate. The company issued in-line guidance for fiscal year 2012 with EPS of $2.25-2.35, excluding non-recurring items, versus the $2.28 Capital IQ Consensus Estimate, with revenues of $62.2-64.7 billion versus the $62.9 billion Capital IQ Consensus Estimate.
